These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32319006)

  • 1. Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands.
    Beurmanjer H; Luykx JJ; De Wilde B; van Rompaey K; Buwalda VJA; De Jong CAJ; Dijkstra BAG; Schellekens AFA
    CNS Drugs; 2020 Jun; 34(6):651-659. PubMed ID: 32319006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project.
    Dijkstra BA; Kamal R; van Noorden MS; de Haan H; Loonen AJ; De Jong CA
    Drug Alcohol Depend; 2017 Jan; 170():164-173. PubMed ID: 27923198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome.
    Kamal RM; Dijkstra BA; Loonen AJ; De Jong CA
    J Addict Med; 2016; 10(4):229-35. PubMed ID: 27310146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Withdrawal syndrome following chronic use of gamma-hydroxybutyric acid (GHB)].
    Moitroux A; Kestens C
    Rev Med Liege; 2023 Jul; 78(7-8):451-455. PubMed ID: 37560960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-hydroxybutyrate detoxification by titration and tapering.
    de Jong CA; Kamal R; Dijkstra BA; de Haan HA
    Eur Addict Res; 2012; 18(1):40-5. PubMed ID: 22142784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the GHB Withdrawal Syndrome.
    Wolf CJH; Beurmanjer H; Dijkstra BAG; Geerlings AC; Spoelder M; Homberg JR; Schellekens AFA
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34073640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzodiazepine tapering: a prospective study.
    Vikander B; Koechling UM; Borg S; Tönne U; Hiltunen AJ
    Nord J Psychiatry; 2010 Aug; 64(4):273-82. PubMed ID: 20629611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detoxification of patients with GHB dependence].
    de Weert-van Oene GH; Schellekens AF; Dijkstra BA; Kamal R; de Jong CA
    Tijdschr Psychiatr; 2013; 55(11):885-90. PubMed ID: 24242149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approach for detoxification of patients dependent on benzodiazepines and Z-drugs for reduction of psychogenic complications.
    Kubová K; Franc A; Vysloužil J; Šaloun J; Vetchý D
    Ceska Slov Farm; 2019; 68(4):139-147. PubMed ID: 31822106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study.
    Gerra G; Zaimovic A; Giusti F; Moi G; Brewer C
    Addict Biol; 2002 Oct; 7(4):385-95. PubMed ID: 14578014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review.
    Kamal RM; van Noorden MS; Franzek E; Dijkstra BA; Loonen AJ; De Jong CA
    Neuropsychobiology; 2016; 73(2):65-80. PubMed ID: 27003176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.
    Basińska-Szafrańska A
    Eur J Clin Pharmacol; 2021 Jun; 77(6):795-808. PubMed ID: 33388822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol.
    Liao PC; Chang HM; Chen LY
    J Formos Med Assoc; 2018 Dec; 117(12):1124-1127. PubMed ID: 29933901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.
    Stein MD; Kanabar M; Anderson BJ; Lembke A; Bailey GL
    J Subst Abuse Treat; 2016 Sep; 68():57-61. PubMed ID: 27431047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking.
    Basińska-Szafrańska A
    Eur J Clin Pharmacol; 2022 Jan; 78(1):101-110. PubMed ID: 34515812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus benzodiazepine.
    Addolorato G; Balducci G; Capristo E; Attilia ML; Taggi F; Gasbarrini G; Ceccanti M
    Alcohol Clin Exp Res; 1999 Oct; 23(10):1596-604. PubMed ID: 10549990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment].
    van Noorden MS; Kamal R; de Jong CA; Vergouwen AC; Zitman FG
    Ned Tijdschr Geneeskd; 2010; 154():A1286. PubMed ID: 21040601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
    Leone MA; Vigna-Taglianti F; Avanzi G; Brambilla R; Faggiano F
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006266. PubMed ID: 20166080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.
    Bennett WR; Wilson LG; Roy-Byrne PP
    J Psychoactive Drugs; 2007 Sep; 39(3):293-6. PubMed ID: 18159783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GHB, GBL and 1,4-BD addiction.
    Brunt TM; van Amsterdam JG; van den Brink W
    Curr Pharm Des; 2014; 20(25):4076-85. PubMed ID: 24001290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.